MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z
  • Randomized controlled trial of 1Hz SMA rTMS + gait training for Freezing of Gait

    G. Revuelta, D. Lench, C. Hanlon, A. Hydar, W. Devries, S. Kautz (Charleston, SC, USA)

  • Randomized, placebo-controlled, double-blind, two-period cross-over study to evaluate the safety, tolerability, and efficacy of a novel treatment combination for levodopa induced dyskinesia in Parkinson’s Disease (BUS-PD)

    K. Chung, B. Lobb, S. O'Connor (Portland, OR, USA)

  • Rapid improvement in dystonia after pallidal deep brain stimulation in a patient with myoclonus-dystonia syndrome: A case report

    L. Deuel, J. Thompson, L. Kahn, J. Barr, A. Abosch, D. Kern (Aurora, CO, USA)

  • Rapid Picture Naming in Parkinson’s Disease Using the Mobile Universal Lexicon Evaluation System (MULES) Test

    J. Conway, C. Gonzalez, S. Fallon, J. Martone, L. Hasanaj, A. Lepor, L. Serrano, J. Rucker, S. Galetta, S. Frucht, L. Balcer (New York, NY, USA)

  • Rapidly onset progressive generalised dystonia parkinsonism in a young Indian male with rare FBXO 7 genetic mutation

    S. Desai, N. Pampaniya, K. Mori, K. Shah (Vadodara, India)

  • Rapidly progressive cognitive decline and hemi-dystonia due to anti-neuronal surface antibodies

    F. Rolim, L. Mendes, P. Braga Neto, R. Sampaio, G. Ferreira, P. Nóbrega, V. Mesquita, F. Maia (Fortaleza, Brazil)

  • Rare causes of Opsoclonus Myoclonus Ataxia Syndrome

    A. Venkitachalam, N. Chaudhary (Mumbai, India)

  • Rare manifestation of CNS Lupus: Parkinsonism

    C. Wantaneeyawong, K. Kumchana (Chiang Mai, Thailand)

  • RDP is associated with bulbar and limb weakness: broadening the phenotype of ATP1A3+ Rapid-Onset Dystonia-Parkinsonism (RDP)

    I. Haq, B. Snively, J. Cook, C. Suerken, K. Sweadner, L. Ozelius, C. Whitlow, A. Brashear (Winston Salem, NC, USA)

  • Re-emergent tremor provocation

    M. Wilken, M. Rossi, A. Rivero, M. Hallett, M. Merello (Buenos Aires, Argentina)

  • Re-emerging Neuroleptic Malignant Syndrome (NMS) without Re-introduced Neuroleptic in a Schizophrenia Patient: a Case Report

    D. Tunjungsari, A. Tiksnadi (Jakarta, Indonesia)

  • Real World Clinical Outcomes Using a Novel Directional Lead from a Multicenter Registry of Deep Brain Stimulation for Parkinson’s Disease

    J. Vesper, R. Jain, A. Wang, H. Scholtes, V. Study Group, G. Deuschl (Düsseldorf, Germany)

  • Real-life gait performance as a marker for motor fluctuations: the Parkinson@home Validation study

    L. Evers, J. Raykov, R. Badawy, K. Claes, M. Meinders, J. Krijthe, T. Heskes, M. Little, B. Bloem (Nijmegen, Netherlands)

  • Reconstructing the history of Machado-Joseph disease

    A. Meira, J. Pedroso, F. Germiniani, O. Barsottini, H. Teive (São Paulo, Brazil)

  • Reduced interhemispheric and premotor-motor connectivity during handwriting in patients with writer’s cramp

    N. Thirugnanasambandam, T. Zimmermann, A. Pillai, J. Shields, S. Horovitz, M. Hallett (Bethesda, MD, USA)

  • Reducing Ataxic Side Effects from VIM DBS Implantation in Essential Tremor: Advantages of Directional Stimulation

    D. Roque (Chapel Hill, NC, USA)

  • Regardless of impaired renal function, negative myoclonus can be induced by gabapetin and pregabalin

    DY. Kwon, MH. Park (Gyenggi-Do, Republic of Korea)

  • Regional subcortical volumes predict gait decline in early Parkinson’s disease

    J. Wilson, R. Lawson, B. Galna, A. Yarnall, S. Lord, R. Morris, L. Alcock, G. Duncan, T. Khoo, D. Burn, L. Rochester, J-P. Taylor (Newcastle Upon Tyne, United Kingdom)

  • Registration Algorithm of DBS Preoperative Image and ICBM-152 Atlas

    H. Zheng, S. Luo, S. Cao, D. Huang, C. Xu (Nanjing, China)

  • Relating web-based-visuo-perception to cognition and genetic variability in Parkinson’s disease: interim report

    A. Costantini, M. Tan, M. Lo, L. Leyland, H. Morris, R. Weil (London, United Kingdom)

  • Relations of clinical symptoms with dopamine transporter imaging in untreated Parkinson’s disease

    Y. Mito, H. Yaguchi, Y. Tajima (Sapporo, Japan)

  • Relationship between cognitive performance and mobility in Parkinson’s disease

    A. Amara, K. Wood, A. Joop, R. Memon, J. Pilkington, M. Bamman, C. Hurt (Birmingham, AL, USA)

  • Relationship between cognitive performance and mobility in patients with Parkinson´s disease: A cross-sectional study

    N. Sousa, R. Macedo, S. Brucki (Salvador, Brazil)

  • Relationship between daily physical activity measured by a triaxial accelerometer and motor symptoms in patients with Parkinson’s disease

    H. Terashi, H. Mitoma, T. Taguchi, H. Aizawa (Tokyo, Japan)

  • Relationship between eye movements during natural reading and basic oculomotor tasks in PD

    J. Waldthaler, L. Stock, C. Krüger-Zechlin, L. Timmermann (Marburg, Germany)

  • Relationship between functional exercise capacity and balance in patients with idiopathic Parkinson’s disease

    BO. Ugut, T. Kahraman, AC. Kalkan, B. Donmez Colakoglu, A. Genc (Izmir, Turkey)

  • Relationship Between Handgrip and Functional Mobility in a Brazilian Parkinsonian Elderly Population

    L. Leandro, S. Kusma, H. Teive, C. Moreira (Curitiba, Brazil)

  • Relationship between intestinal bacteria, bacterial metabolites and residual pesticides in Parkinson’s disease

    M. Hirayama, T. Hamaguchi, M. Ito, T. Ishida, M. Kuki, T. Maeda, K. Kashihara, Y. Tsuboi, K. Ohno (Hukuoka, Japan)

  • Relationship between non-motor symptoms, medications and sleep interruptions in patients with Parkinson’s disease

    S. Anis, A. Thaler, M. Kestenbaum, A. Orr-Urtreger, M. Gana-Weisz, O. Goldstein, R. Hen Simon, J. Cederbaum, J. Hausdorff, N. Giladi, A. Mirelman (Tel Aviv, Israel)

  • Relationship between pain and autonomic symptoms in Parkinson’s Disease: a double-center, cross-sectional, observational study.

    P. Imbriani, P. Ghosh, T. Schirinzi, N. Caputi, L. Covington, A. Sparks, Y. Salnikova, S. Natoli, A. Pisani (Rome, Italy)

  • Relationship between parkinsonism and upper extremity function in patients with Parkinson’s disease

    H. Sawada, M. Takahashi, A. Inaba, S. Orimo (Tokyo, Japan)

  • Relationship between Progressive Supranuclear Palsy and Caregiver Burden

    Y. Inuzuka, J. de Courcy, J. Pike, J. Mellor, E. Viscidi, A. Paradis, A. Harrington, Y. Zabar (Zug, Switzerland)

  • Relationship between RBD and olfactory disorder, clinical symptoms in Parkinson’s disease

    M. Iijima, F. Yoshi, K. Suzuki, S. Nogawa, T. Osada, H. Hirata, K. Kitagawa, N. Hattori, Y. Okuma (Tokyo, Japan)

  • Relationship between restless legs syndrome and various factors in pregnancy

    L. čondić, S. Telarović (Zagreb, Croatia)

  • Relationship between serum uric acid and the pattern of striatal dopamine depletion in De Novo Parkinson’s disease

    K. Baik, Y. Lee, S. Chung, H. Yoo, J. Jung, P. Lee (Seoul, Republic of Korea)

  • Relationship between striatal dopamine depletion and various non-motor symptoms in non-demented patients with Parkinson’s disease: a pilot study

    JY. Lee, H. Ju, K. Im, MY. Ahn, KY. Kwon (Seoul, Republic of Korea)

  • Relationship between symptoms and regional density of metabotropic glutamate receptors subtype 1 measured with 11C-ITMM PET in de novo Parkinson’s disease

    K. Ishiwata, K. Kimura, MR. Zhang, J. Toyohara, K. Wagatsuma, M. Sakata, K. Ishibashi, K. Ishii, M. Suzuki, M. Mishina (Kawasaki, Japan)

  • Relationship of cognitive processing speed with postural stability in non-demented Parkinson’s disease patients

    J. Andreo Jover, A. Arroyo Ferrer, P. López Serrano, J. Periañez, M. Rios-Lago, G. Lubrini, JP. Romero Muñoz (Madrid, Spain)

  • Relationships of gender, care models, and neuropsychiatric symptoms in Parkinson’s disease

    J. Goldman, S. Wu, C. Martinez-Rubio, V. Todaro (New York, NY, USA)

  • Relative Preservation of Serotonergic Function Increases Response to Treatment in Early PD

    J. Fu, M. Matarazzo, I. Klyuzhin, K. Cheng, C. Bevington, J. Mckenzie, N. Heffernan, E. Shahinfard, M. Mckeown, AJ. Stoessl, V. Sossi (Vancouver, BC, Canada)

  • Reliability and Validity of Modified Four Square Step Test (mFSST) Performance in Individuals with Parkinson’s Disease.

    A. Boddy, K. Mitchell, W. Brewer, J. Ellison, L. Perry, C. Andrea (St. Augustine, FL, USA)

  • Reliability, feasibility and validity of a novel digital monitoring platform assessing cognitive and motor symptoms in people with Stage I and II Huntington’s disease (HD)

    F. Lipsmeier, C. Simillion, A. Atieh Bamdadian, A. Smith, S. Schobel, C. Gossens, P. Weydt, E. Wild, M. Lindemann (Basel, Switzerland)

  • REM density in isolated REM sleep without atonia

    F. Dijkstra, M. Viaene, I. de Volder, P. Cras, D. Crosiers (Geel, Belgium)

  • REM sleep behavior disorder and REM sleep without atonia is a progression marker in Parkinson’s disease: a report from the DeNoPa cohort

    F. Sixel-Döring, L. Zimansky, ML. Muntean, B. Mollenhauer, C. Trenkwalder (Kassel, Germany)

  • Repetitive transcranial magnetic stimulation (rTMS) for the treatment of pain in Parkinson’s Disease – an open-label study

    M. Bonello, T. Nurmikko, A. Mavrianou, M. Steiger (Liverpool, United Kingdom)

  • Repetitive transcranial magnetic stimulation can improve anxiety in Parkinson’s disease: a randomized, double-blind and controlled trial

    A. Makkos-Weisz, N. Kovács, P. Endre, M. Kovács, D. Pintér (Pécs, Hungary)

  • Repetitive transcranial magnetic stimulation does not improve the sequence effect in freezing of gait

    L. Gao, T. Mi, T. Wu, P. Chan (Beijing, China)

  • Research on the modifier gene of Hereditary spinocerebellar ataxia type 2

    JLW. Wang, ZL. Liu (Changsha, China)

  • Respiratory Function and Functional Decline in Spinocerebellar Ataxia Type 2

    N. Mello, M. Zonta, H. Teive, A. Meira, B. Zeigelboim (Curitiba, Brazil)

  • Resting state functional connectivity changes in dystonia

    A. Vo, N. Nguyen, K. Schindlbeck, D. Eidelberg (Manhasset, NY, USA)

  • Resting state Functional Connectivity differences in Pediatric Patients with Tourette syndrome and Obsessive-compulsive disorder

    S. Tikoo, F. Cardona, S. Tommasin, C. Giannì, N. Upadhyay, K. Bharti, G. Conte, G. Mirabella, A. Suppa, P. Pantano (Roma, Italy)

  • Resting-state EEG functional connectivity in Parkinson’s disease

    R. Shoorangiz, E. Peterson, R. Jones, L. Livingston, I. Kirk, L. Tippett, M. Livingstone, T. Anderson, J. Dalrymple-Alford (Christchurch, New Zealand)

  • Resting-state EEG spectral power in Parkinson’s disease

    J. Dalrymple-Alford, R. Shoorangiz, E. Petersen, R. Jones, B. Elias, L. Livingston, I. Kirk, L. Tippett, M. Livingstone, T. Anderson (Christchurch, New Zealand)

  • Resting-State fMRI in Essential Tremor after MRgFUS treatment

    C. Kindler, V. Purrer, N. Upadhyay, V. Keil, V. Borger, C. Pieper, L. Scheef, H. Boecker, U. Wuellner (Bonn, Germany)

  • Restless Genital Syndrome in a patient with Dementia with Lewy Body

    M. Abu Al-Melh, M. Farghal, B. Al-Failakawii (Kuwait, Kuwait)

  • Restless Leg Syndrome In Men: Examination Of Early Non-Motor Clinical Signs Of Parkinson’s Disease

    M. şenol, M. Karaoğlan, H. Tekeli (Istanbul, Turkey)

  • Restless leg syndrome in Neuro-Behcet’s and Behcet’s disease

    M. Kuzu Kumcu, S. Erdoğan, M. Sorgun, C. Yücesan (Ankara, Turkey)

  • Restless legs syndrome in a patient with hereditary hemochromatosis

    Z. Fatima, S. Wijemanne (San Antonio, TX, USA)

  • Restoring AADC enzyme synthesis in AADC deficiency: MRI-Guided Delivery of AAV2-hAADC Gene Therapy to the Midbrain

    K. Bankiewicz, T. Pearson, A. Grijalvo-Perez, A. Viehoever, W. San Sebastian, J. Imamura-Ching, Y. Seo, P. Larson, N. Gupta (San Francisco, CA, USA)

  • Results of community pharmacist-led structured medication reviews in Parkinson’s Disease

    N. Oonk, P. Oude Avenhuis, K. Movig, K. Koehorst-Ter Huurne, WH. Nijmeijer, M. van Kesteren-Biegstraaten, J. Vd Palen, L. Dorresteijn (Enschede, Netherlands)

  • Retinal layer thinning in de novo Parkinson’s disease

    A. Chrysou, N. Jansonius, T. van Laar (Groningen, Netherlands)

  • Retinal thickness and microvascular pattern in early Parkinson’s disease.

    C. Rascunà, C. Terravecchia, A. Russo, G. Mostile, CE. Cicero, A. Luca, N. Castellino, A. Longo, T. Avitabile, M. Reibaldi, M. Zappia, A. Nicoletti (Catania, Italy)

  • Retronasal olfactory function in Parkinson’s disease

    E. Aubry-Lafontaine, C. Tremblay, P. Durand-Martel, N. Dupré, J. Frasnelli (Trois-Rivières, QC, Canada)

  • Retrospective analysis of hospitalized Parkinson ‘s disease patients from 2002 to 2014 in Suzhou district

    C. Mao, J. Chen, H. Gu, D. Chen, J. Huang, J. Chen, Y. Wang, W. Luo, C. Liu (Changshu, China)

  • Reverse phenotyping of a 3.3Mb loss of 8p11.21p11.1, including SLC20A2, lead to a diagnosis of primary familial brain calcification

    A. Kievit, L. Zutven, A. Boon (Rotterdam, Netherlands)

  • Reviewing the clinical and mutational spectrum of SLC20A2, PDGFB, PDGFRB, XPR1 and MYORG mutations in Primary Familial Brain Calcification (PFBC) for MDSGene

    A. Balck, S. Schaake, J. Margolesky, A. Domingo, C. Klein, A. Westenberger (Lubeck, Germany)

  • Rhythmic disorders in idiopathic RBD: a potential new marker for future PD?

    V. Cochen Decock, D. Verbizier, C. Geny, S. Dalla Bella (Montpellier, France)

  • RimbotulinumtoxinB in the treatment of adult sialorrhea

    S. Isaacson, W. Ondo, M. Lew, K. Dashtipour, D. Chary, T. Clinch, F. Pagan (Boca Raton, FL, USA)

  • Risk of developing the Parkinson’s disease against the background of diabetes mellitus type 2.

    F. Akhmedova, M. Tukhtamishev (Tashkent, Uzbekistan)

  • Risk of Parkinson’s in idiopathic anosmia

    R. Rees, S. Gane, C. Philpott, A. Noyce, A. Schrag (Norwich, United Kingdom)

  • Risk Thresholds of Levodopa Dose for Dyskinesia in Chinese Patients with Parkinson’s Disease: A Pilot Study

    GL. Liu, T. Feng (Beijing, China)

  • Rivastigmine for visual hallucinations in Parkinson’s disease

    T. Mierlo, E. Foncke, R. Bie (Amsterdam, Netherlands)

  • RNA binding protein mediated regulation of striatal transcriptome in Parkinson’s disease.

    K. Irmady, C. Hale, C. Scheckel, J. Fak, R. Darnell (New York, NY, USA)

  • Role of Alzheimer’s Disease Genetic Risk Variant rs9331896 in Cognitive Decline in Parkinson’s Disease

    T. Tropea, L. Baratta, K. Maddy, M. Guo, J. Rick, V. van Deerlin, J. Trojanowski, D. Weintraub, A. Chen-Plotkin (Philadelphia, PA, USA)

  • Role of APOE ε4 status and Sex on Somatosensory Integration and Dual-Task Cost in Parkinson’s disease

    D. Martini, R. Morris, G. Mcbarron, T. Madhyastha, T. Grabowski, SC. Hu, C. Zabetian, A. Hiller, K. Chung, J. Quinn, F. Horak (Portland, OR, USA)

  • Role of clinical neuroimaging in X-linked dystonia-parkinsonism

    J. Junker, A. Neumann, R. Rosales, D. Jamora, C. Diesta, J. Prasuhn, T. Muente, C. Klein, P. Schramm, N. Brueggemann (Luebeck, Germany)

  • Role of microRNA-153 and -223 in Parkinson disease

    M. Cressatti, W. Song, L. Jawura, J. Galindez, O. Canie, A. Velly, M. Gornitsky, H. Schipper (Montreal, QC, Canada)

  • Role of pallidotomy in secondary dystonia in pediatric patients

    K. Garg, M. Singh, V. Goyal (New Delhi, India)

  • rTMS-induced effects on Functional Tremor: a randomized, double-blind, controlled study

    S. Taib, F. Ory-Magne, C. Brefel-Courbon, Y. Moreau, C. Thalamas, C. Arbus, M. Simonetta-Moreau (Toulouse, France)

Jump to:  View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Safety and Tolerability of a Ketone Supplement in Parkinson's Disease
  • Successful external defibrillation in a patient with bilateral deep brain stimulation
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley